Intrexon Corporation (NYSE:XON) had its target price reduced by analysts at Bank of America Corporation from $25.00 to $21.00 in a research report issued to clients and investors on Friday. The firm presently has a “neutral” rating on the biotechnology company’s stock. Bank of America Corporation’s price target suggests a potential upside of 77.82% from the company’s previous close.
A number of other brokerages have also recently weighed in on XON. Zacks Investment Research cut Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Northland Securities set a $30.00 price target on Intrexon Corporation and gave the company a “buy” rating in a research report on Monday, August 7th. BidaskClub cut Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Griffin Securities reiterated a “buy” rating and issued a $55.00 price target on shares of Intrexon Corporation in a research report on Friday, October 6th. Finally, JMP Securities reiterated an “outperform” rating and issued a $42.00 price target on shares of Intrexon Corporation in a research report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $38.50.
Shares of Intrexon Corporation (XON) opened at $11.81 on Friday. Intrexon Corporation has a 1 year low of $11.80 and a 1 year high of $32.90. The company has a quick ratio of 2.25, a current ratio of 2.45 and a debt-to-equity ratio of 0.01.
Intrexon Corporation (NYSE:XON) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 18.59% and a negative net margin of 66.88%. The firm had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. During the same period in the prior year, the business posted ($0.42) earnings per share. The business’s revenue was up 3.6% compared to the same quarter last year. equities research analysts anticipate that Intrexon Corporation will post -0.84 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/11/12/bank-of-america-corporation-lowers-intrexon-corporation-xon-price-target-to-21-00.html.
In other Intrexon Corporation news, Director Robert B. Shapiro acquired 2,850 shares of Intrexon Corporation stock in a transaction on Tuesday, August 22nd. The shares were bought at an average price of $17.50 per share, with a total value of $49,875.00. Following the completion of the purchase, the director now owns 43,157 shares in the company, valued at $755,247.50. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Andrew J. Last acquired 2,000 shares of Intrexon Corporation stock in a transaction on Monday, August 14th. The stock was acquired at an average cost of $19.99 per share, for a total transaction of $39,980.00. Following the purchase, the chief operating officer now owns 2,000 shares of the company’s stock, valued at approximately $39,980. The disclosure for this purchase can be found here. 55.10% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of XON. UBS Asset Management Americas Inc. boosted its stake in Intrexon Corporation by 16.7% in the first quarter. UBS Asset Management Americas Inc. now owns 33,333 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 4,773 shares in the last quarter. Teachers Advisors LLC boosted its stake in Intrexon Corporation by 6.8% in the first quarter. Teachers Advisors LLC now owns 53,606 shares of the biotechnology company’s stock worth $1,062,000 after purchasing an additional 3,434 shares in the last quarter. Legal & General Group Plc boosted its stake in Intrexon Corporation by 102.5% in the first quarter. Legal & General Group Plc now owns 18,450 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 9,340 shares in the last quarter. Vanguard Group Inc. boosted its stake in Intrexon Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock worth $84,954,000 after purchasing an additional 226,090 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Intrexon Corporation by 3.5% in the first quarter. Geode Capital Management LLC now owns 429,532 shares of the biotechnology company’s stock worth $8,513,000 after purchasing an additional 14,674 shares in the last quarter. 82.10% of the stock is currently owned by institutional investors.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.